A Clinical Study of HRS-7525 Tablets in Patients With Advanced Prostate Cancer

Summary

The purpose of this study is to evaluate the safety and tolerability of HRS-7525 in participants with Advanced Prostate Cancer, and to determine the dose limiting toxicity (DLT), the maximum tolerated dose (MTD, if possible), and the recommended Phase II dose (RP2D) of HRS-7525.

Timeline

Start

2026-07

Primary completion

2028-06

Completion

2029-12

Drugs

Indications